Billionaire Profile
Yusuf Hamied
Global Rank
#1668

Image: India Post, Government of India | GODL-India | via Wikimedia Commons

Yusuf Hamied

CEO, Pharmaceuticals
INDIA
Real-Time Net Worth
$2.463B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
-0.28% (24h)
Age
89
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
INDIA

Biography

Dr. Yusuf Khwaja Hamied is an 89-year-old Indian scientist and billionaire businessman, renowned for his pioneering role in the pharmaceutical industry. He is the non-executive chairman of Cipla, a global generic pharmaceuticals company. His wealth stems from his strategic vision in making affordable medications available to the masses, especially in developing countries. Hamied's career has been marked by his determination to challenge large pharmaceutical companies and provide life-saving drugs at significantly reduced costs, earning him recognition as a modern-day humanitarian. His achievements include transforming Cipla into a global leader and receiving the Padma Bhushan award.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Yusuf Khwaja Hamied was born on July 25, 1936, in Vilnius, Lithuania (then Poland). Raised in Mumbai, he was the son of an Indian Muslim father and a Russophone Lithuanian Jewish mother. He received his early education at Cathedral and John Connon School and St. Xavier's College in Mumbai.

Rise to Success

Hamied pursued a Bachelor of Arts degree in Chemistry from Christ's College, Cambridge, and later earned a Ph.D. from the same institution. He joined Cipla, a pharmaceutical company founded by his father, Khwaja Abdul Hamied, in 1935, and eventually became chairman. Hamied is best known for challenging the dominance of Western pharmaceutical companies by providing low-cost generic drugs, especially for diseases prevalent in poor countries, such as AIDS. He has been credited with making life-saving medicines affordable to those in need, leading to him being characterized as a modern-day Robin Hood.

Key Business Strategies

Hamied's business strategies have focused on producing generic drugs and making them available at significantly lower prices than those of branded pharmaceutical companies. He spearheaded Cipla's expansion and pioneered multi-drug combination pills for HIV/AIDS, asthma, and tuberculosis. His willingness to challenge the established order and focus on affordability revolutionized access to essential medicines, particularly in developing countries.

Philanthropy

Hamied is actively involved in philanthropy. He has supported educational and research institutions, including the Yusuf Hamied Department of Chemistry at Cambridge University and IISER Pune. He also established the Yusuf and Farida Hamied Foundation, dedicated to advancing global health equity by investing in palliative care, rare diseases, and scientific education.

Career Milestones

1960

Joined Cipla

Joined Cipla after completing his Ph.D. in chemistry at Cambridge.

1976

Managing Director of Cipla

Became the Managing Director of Cipla.

1989

Chairman of Cipla

Became the Chairman of Cipla.

2000

Made Historic Speech

Made a historic speech at the European Commission highlighting the need for affordable HIV/AIDS treatments.

2001

Dollar-a-Day Offer

Offered a dollar-a-day treatment to Médecins Sans Frontières (MSF).

Philanthropy & Social Impact

Education

Yusuf Hamied Department of Chemistry

Undisclosed

Donated to Cambridge University's Department of Chemistry

Healthcare

Yusuf and Farida Hamied Foundation

Undisclosed

Supports equitable healthcare access worldwide.

Healthcare

Cipla Palliative Care Centre

Undisclosed

Established the Cipla Palliative Care Centre in Pune.

Business Philosophy & Leadership

Notable Quotes

""I don't want to make money off these diseases which cause the whole fabric of society to crumble.""

""I've done more humanitarian work than Bill Gates and Warren Buffett put together.""

Leadership Principles

Affordability

Committed to providing affordable medicines to those in need.

Innovation

Pioneered the development of multi-drug combination pills.

Social Responsibility

Dedicated to improving access to healthcare for all, especially in developing nations.